Loading company…
Ousia Pharma develops peptide-drug conjugates for cardiometabolic diseases.
Ousia Pharma develops peptide-drug conjugates for cardiometabolic diseases, using targeted delivery to appetite-control regions of the brain. Its therapies are intended to support appetite and energy-balance regulation. Founded in 2022, the company is based in Copenhagen, Denmark. In May 2025, it raised an undisclosed Seed round led by Omega Funds to support clinical trials and product development.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in